-
The FDA has approved a once-weekly treatment for type 2 diabetes. The new product is a subcutaneously administered extended-release form of the glucagon-like peptide-1 receptor agonist, exenatide. Exenatide extended-release is marketed by Amylin Pharmaceuticals and Alkermes PLC as Bydureon.
-
Zinc deficiency is defined as a serum zinc level < 60 mg/dL. Unfortunately, there is some question about the reliability of zinc levels to accurately reflect zinc status, since some persons with prototypic symptoms of zinc deficiency (loss of appetite, diarrhea, hair loss, delayed wound healing, and smell and taste disturbances) have normal zinc levels.
-
Aspirin can reduce the risk of nonfatal myocardial infarction, but not mortality, in people without coronary vascular disease, at the expense of increased risk of bleeding. It should not be routinely recommended.
-
In November 2011, the Centers for Disease Control and Prevention presented data on emergency hospitalizations because of adverse drug reactions. The report showed that insulin and oral hypoglycemic agents caused nearly 25% of the medication-induced hospitalizations in older adults in the United States.
-
When routinely cultured, essentially all ICU privacy curtains were found to be contaminated with potential pathogens at least some of the time. Recovered organisms included methicillin-resistant staphylococci and vancomycin-resistant enterococci.
-
In this study population with a 2% average risk of a major coronary event per year, LDL cholesterol, apolipoproteins, and LDL particle concentrations had similar and strong associations for major vascular events. The independent predictive value of HDL measures is less clear.
-
Clinical Briefs: Coffee Might be One Less Thing We Have to Worry About; ED, Lower Urinary Tract Symptoms, and Ejaculatory Dysfunction; The Allure of Shared Medical Appointments in Diabetes Care
-
A BETA-3 ADRENERGIC AGONIST HAS BEEN APPROVED FOR the treatment of overactive bladder in adults. Mirabegron differs from other agents approved for this same indication, such as oxybutynin, tolterodine, solifenacin, darifenacin, etc., which are anticholinergic/antimuscarinic agents. Mirabegron is marketed by Astellas Pharma as Myrbetriq.
-
-
The practice of tanning by artificial means, such as by sunlamps or sunbeds, continues to be popular, particularly in young people despite the acknowledged risk for increased skin cancer.
